

TAF II p135/p105 Polyclonal Antibody

Description

Product type	Primary Antibody
Code	BT-AP08791
Host	Rabbit
Isotype	IgG
Size	20ul, 50ul, 100ul
Immunogen	The antiserum was produced against synthesized peptide derived from human TAF4. AA range:941-990
Mol wt	110114
Species reactivity	Human, Mouse
Clonality	Polyclonal
Recommended application	WB, IHC-p, ELISA
Concentration	1 mg/ml
Full name	TAF II p135/p105 Antibody
Synonyms	TAF4; TAF2C; TAF2C1; TAF4A; TAFII130; TAFII135; Transcription initiation factor TFIID subunit 4; RNA polymerase II TBP-associated factor subunit C; TBP-associated factor 4; Transcription initiation fa

This product is for research use only, not for use in human, therapeutic or diagnostic procedure.

Background

Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. TAF4 (TATA-box binding protein associated factor 4) encodes one of the larger subunits of TFIID that has been shown to potentiate transcriptional activation by retinoic acid, thyroid hormone and vitamin D3 receptors. In addition, this subunit interacts with the transcription factor CREB, which has a glutamine-rich activation domain, and binds to other proteins containing glutamine-rich regions. Aberrant binding to this subunit by proteins with expanded polyglutamine regions has been suggested as one of the pathogenetic mechanisms underlying a group of neurodegenerative disorders referred to as polyglutamine diseases.

Recommended Dilution


WB: 1: 500 - 1: 2000

IHC: 1: 100 - 1: 300

ELISA: 1: 20000

Not yet tested in other applications.

Images



Western blot analysis of lysates from NIH/3T3 cells, using TAF4 Antibody. The lane on the right is blocked with the synthesized peptide.

Storage

-20°C for one year

501 Changsheng S Rd, Nanhu Dist, Jiaxing, Zhejiang, China

Tel: 86 21 31007137 | E-mail: save@bt-laboratory.com | www.bt-laboratory.com